Publications

Resistance or Defiance? The FDA and the 11th Circuit Spar Over Statute on Orphan Drug Statutory Exclusivity

Co-Author, Clinical Leader

Chad Landmon, Hatch-Waxman & Biologics Chair, discusses the challenges to the FDA's interpretation of the Orphan Drug Act.